Through the integration of human expertise, artificial intelligence, and automation robotics, bio/pharma companies can more efficiently target drug discovery efforts with bigger payoff.
Kenji Tabata
Advertisement
Kenji Tabata, PhD, is senior vice-president, head of Discovery Intelligence, Applied Research & Operations, at Japan-based pharmaceutical company Astellas.
Articles by Kenji Tabata
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Analytics, Automation, and Quality Driving the Next Era of Drug Development
5
